New combo therapy aims to tame rare lymphoma without lifelong drugs
NCT ID NCT07380984
First seen Feb 02, 2026 · Last updated May 15, 2026 · Updated 14 times
Summary
This study tests a combination of a PD-1 antibody (a type of immunotherapy) and radiation therapy for people with early-stage nasal-type NK/T-cell lymphoma who have not had treatment before. The goal is to see if this approach can control the disease longer and with fewer side effects. About 47 adults will take part, and the main measure is how long they stay free of cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NATURAL KILLER/T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital, Shanghai JiaoTong University School of Medicine
RECRUITINGShanghai, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.